Ofloxacin for injection

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative rods, and has good antibacterial activity against the following bacteria in vitro: 1. Most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It also has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae, and Moraxella. 2. It has antibacterial activity against most strains of Pseudomonas, such as Pseudomonas aeruginosa. 3. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus, and Enterococcus faecalis. It has good antimicrobial effects against Chlamydia trachomatis, Mycoplasma, and Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. 4. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. The drug resistance of this product is currently increasing, and there is cross-resistance with other quinolones.

The main ingredient of this product is ofloxacin.

Applicable to the following cases caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis caused by Neisseria gonorrhoeae (including those caused by enzyme-producing strains). 2. Respiratory tract infections, including acute onset of bronchial infection and lung infection caused by sensitive Gram-negative bacteria. 3. Gastrointestinal tract infections caused by Shigella, Salmonella, and enterotoxigenic Escherichia coli.

Slow intravenous drip. .Used dosage for adults: 1. Bronchial infection, lung infection: 0.3g once, twice a day, course of treatment 7 to 14 days. 2. Acute simple lower urinary tract infection: 0.2g once, twice a day, course of treatment 5 to 7 days; complicated urinary tract infection: 0.2g once, twice a day, 10 to 14 days. 3. Prostatitis: 0.3g once, twice a day, course of treatment 6 weeks; Chlamydia cervicitis or urethritis, 0.3g once, twice a day, course of treatment 7 to 14 days. 4. Simple gonorrhea: 0.4g once, single dose. 5. Typhoid fever: 0.3g once, twice a day, course of treatment 10 to 14 days. 6. Pseudomonas aeruginosa infection or severe infection: the dose can be increased to 0.4g once, twice a day.

1. Gastrointestinal reactions: abdominal discomfort or pain, diarrhea, nausea or vomiting. 2. Central nervous system reactions: dizziness, headache, drowsiness or insomnia. 3. Allergic reactions: rash, itchy skin, occasionally exudative erythema multiforme and angioneurotic edema. Photosensitivity reactions are less common. 4. Occasionally: epileptic seizures, mental abnormalities, irritability, confusion, hallucinations, tremors. Manifestations of interstitial nephritis such as hematuria, fever, and rash. Phlebitis. Crystalluria, more common in high doses. Joint pain. 5. A small number of patients may experience elevated serum aminotransferase, increased blood urea nitrogen, decreased peripheral white blood cells, and irritation symptoms at the injection site, which are mostly mild and transient.

Patients who are allergic to this product and fluoroquinolones are contraindicated.

Precautions for children: 1. The safety of this product in children and adolescents under 18 years of age has not been established. 2. This product can cause joint lesions when used in several young animals. Therefore, it is not suitable for children and adolescents under 18 years of age. Precautions for pregnancy and lactation: 1. Animal experiments have not confirmed that quinolones are teratogenic, but studies on the use of drugs in pregnant women have not yet reached a clear conclusion. Since this drug can cause joint lesions in underage animals, it is contraindicated for pregnant women. 2. Breastfeeding women need to suspend breastfeeding. Precautions for the elderly: Elderly patients often have impaired renal function. Since this product is partially excreted through the kidneys, it needs to be used in reduced doses. Or follow the doctor's advice.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver clearance of theophylline, a prolonged blood elimination half-life (t1/2beta;), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Although this product has a small metabolism of theophylline, theophylline blood drug concentration should still be measured and the dose adjusted when used in combination. 3. When this product is used in combination with cyclosporine, the blood drug concentration of cyclosporine can be increased. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4. When this product is used in combination with the anticoagulant warfarin, although the anticoagulant effect of the latter is slightly enhanced, the patient's prothrombin time should be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increase in the blood concentration of this product. 6. This product can interfere with the metabolism of caffeine, thereby reducing the clearance of caffeine, prolonging the blood elimination half-life (t1/2beta;), and may cause central nervous system toxicity.

Keep in a dark, airtight, cool and dry place

0.1g

Hainan Huluwa Pharmaceutical Group Co., Ltd.

• Founded in:

  2005-06-22

• Address:

  No. 8, Yaogu 4th Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Haikou City, Hainan Province

• Tax NO.:

  91460100774262258E

• Registered Funds:

  400.108752 million yuan

• Website:

  Log in to view

• Email:

  Log in to view